FOXO1 mediates the autocrine effect of endothelin-1 on endothelial cell survival

Molecular Endocrinology

Volumn 26, Issue 7, 2012, Pages 1213-1224

  Cifarelli, Vincenza ^a   Lee, Sojin ^a   Kim, Dae Hyun ^a   Zhang, Ting ^a   Kamagate, Adama ^a   Slusher, Sandra ^a   Bertera, Suzanne ^a   Luppi, Patrizia ^a   Trucco, Massimo ^a   Henry Dong, H ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; INSULIN; PROTEIN BAD; TRANSCRIPTION FACTOR FKHR;

ADENOVIRUS; ANIMAL CELL; AORTA; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; GENE TRANSFER; GLYCOSYLATION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; AORTA; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE; CELL SURVIVAL; DIABETES MELLITUS; ENDOTHELIAL CELLS; ENDOTHELIN-1; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE TRANSFER TECHNIQUES; HUMANS; HYPERGLYCEMIA; INSULIN; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; PHOSPHORYLATION; RANDOM ALLOCATION;

ADENOVIRIDAE; MUS;

EID: 84863324166     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1276     Document Type: Article

References (65)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T 1988 A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415
2. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T 1990 Cloning of a cDNA encoding a non-iso-peptide-selective subtype of the endothelin receptor. Nature 348: 732-735
3. Seligman BG, Biolo A, Polanczyk CA, Gross JL, Clausell N 2000 Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 23:1395-1400
4. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR 1990 Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306-310
5. Wu SQ, Hopfner RL, McNeill JR, Wilson TW, Gopalakrishnan V 2000 Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin resistant obese Zucker rat. Cardiovasc Res 45:994-1000
6. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G 1996 Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45:316-321
7. Piatti PM, Monti LD, Galli L, Fragasso G, Valsecchi G, Conti M, Gernone F, Pontiroli AE 2000 Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism 49:748-752
8. Kohan DE 2010 Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 19:134-139
9. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S 2009 Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 32(Suppl 2):S314-S321
10. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Cour-tois M, Muslin AJ 2006 Akt1 is required for physiological cardiac growth. Circulation 113:2097-2104
11. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J 2005 Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 145: 323-333
12. Pflug BR, Zheng H, Udan MS, D'Antonio JM, Marshall FF, Brooks JD, Nelson JB 2007 Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett 246:139-148
13. del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosanò L, Trisciuoglio D, Spinella F, Bagnato A 2002 Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61:524-532
14. Nelson JB, Udan MS, Guruli G, Pflug BR 2005 Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 7:631-637
15. Liu S, Premont RT, Kontos CD, Huang J, Rockey DC 2003 Endothelin-1 activates endothelial cell nitric-oxide synthase via hetero-trimeric G-protein βγ subunit signaling to protein kinase B/Akt. J Biol Chem 278:49929-49935
16. Accili D, Arden KC 2004 FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117:421-426
17. Barthel A, Schmoll D, Unterman TG 2005 FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 16:183-189
18. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF 2008 Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 8:65-76
19. Lee SS, Kennedy S, Tolonen AC, Ruvkun G 2003 DAF-16 target genes that control C. elegans life-span and metabolism. Science 300:644-647
20. Hwangbo DS, Gershman B, Gershman B, Tu MP, Palmer M, Tatar M 2004 Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 429:562-566
21. Puig O, Tjian R 2006 Nutrient availability and growth: regulation of insulin signaling by dFOXO/FOXO1. Cell Cycle 5:503-505
22. Kamagate A, Dong HH 2008 FoxO1 integrates insulin signaling to VLDL production. Cell Cycle 7:3162-3170
23. Biggs 3rd WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC 1999 Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96:7421-7426
24. Rena G, Prescott AR, Guo S, Cohen P, Unterman TG 2001 Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear target-ting. Biochem J 354:605-612
25. Nakae J, Park BC, Accili D 1999 Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a wortmannin-sensitive pathway. J Biol Chem 274:15982-15985
26. Nakae J, Barr V, Accili D 2000 Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J 19:989-996
27. Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG, Powell DR 1999 FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology 140:3140-3146
28. Schmoll D, Walker KS, Alessi DR, Grempler R, Burchell A, Guo S, Walther R, Unterman TG 2000 Regulation of glucose-6-phospha-tase gene expression by protein kinase Ba and the Forkhead transcription factor FKHR. J Biol Chem 36324-36333
29. Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, Mesecar A, Adam S, Unterman TG 2002 Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 277:45276-45284
30. van Der Heide LP, Hoekman MF, Smidt MP 2004 The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 380:297-309
31. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M 2008 Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-«B pathway. Diabetologia 51: 1534-1543
32. Kwok CF, Juan CC, Ho LT 2007 Endothelin-1 decreases CD36 protein expression in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 292:E648-E652
33. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH 2008 FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 118:2347-2364
34. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH 2004 Foxo1 mediates insulin action on ApoC-III and triglyceride metabolism. J Clin Invest 114:1493-1503
35. Su D, Zhang N, He J, Qu S, Slusher S, Bottino R, Bertera S, Bro-mberg J, Dong HH 2007 Angiopoietin-1 production in islets improves islet engraftment and protects islets from cytokine-induced apoptosis. Diabetes 56:2274-2283
36. Kim DH, Perdomo G, Zhang T, Slusher S, Lee S, Phillips BE, Fan Y, Giannoukakis N, Gramignoli R, Strom S, Ringquist S, Dong HH 2011 Forkhead box O6 integrates insulin signaling with gluconeo-genesis in the liver. Diabetes 60:2763-2774
37. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T 2008 O-glycosylation of FoxO1 increases its transcriptional activity towards the glucose 6-phosphatase gene. FEBS Lett 582:829-834
38. Qu S, Altomonte J, Perdomo G, He J, Fan Y, Kamagate A, Meseck M, Dong HH 2006 Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology 147:5641-5652
39. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T 2008 O-GlcNAc modification of FoxO1 increases its transcriptional activity: a role in the glucotoxicity phenomenon? Biochimie 90:679-685
40. Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, Puigserver P, Hart GW 2008 O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 283:16283-16292
41. Urade Y, Fujitani Y, Oda K, Watakabe T, Umemura I, Takai M, Okada T, Sakata K, Karaki H 1992 An endothelin B receptor-selective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21). FEBS Lett 311:12-16
42. Liu C, Liang B, Wang Q, Wu J, Zou MH 2010 Activation of AMP-activated protein kinase α1 alleviates endothelial cell apopto-sis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin. J Biol Chem 285:15346-15355
43. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ 1993 Bcl-2 functions in an antioxidant pathway to prevent apopto-sis. Cell 75:241-251
44. Oltvai ZN, Milliman CL, Korsmeyer SJ 1993 Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619
45. Danial NN 2008 BAD: undertaker by night, candyman by day. Oncogene 27(Suppl 1):S53-S70
46. Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B, Vallette FM 2007 Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12:887-896
47. Kamagate A, Kim DH, Zhang T, Slusher S, Gramignoli R, Strom SC, Bertera S, Ringquist S, Dong HH 2010 FoxO1 links hepatic insulin action to endoplasmic reticulum stress. Endocrinology 151: 3521-3535
48. Schorlemmer A, Matter ML, Shohet RV 2008 Cardioprotective signaling by endothelin. Trends Cardiovasc Med 18:233-239
49. Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM 2001 Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 61:3294-3298
50. Tanaka J, Qiang L, Banks AS, Welch CL, Matsumoto M, Kitamura T, Ido-Kitamura Y, DePinho RA, Accili D 2009 Foxo1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. Diabetes 58:2344-2354
51. Tsuchiya K, Tanaka J, Shuiqing Y, Welch CL, DePinho RA, Tabas I, Tall AR, Goldberg IJ, Accili D 2012 FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab 15:372-381
52. Formoso G, Chen H, Kim JA, Montagnani M, Consoli A, Quon MJ 2006 Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol 20:1153-1163
53. Chen H, Lin AS, Li Y, Reiter CE, Ver MR, Quon MJ 2008 Dehydroepiandrosterone stimulates phosphorylation of FoxO1 in vascular endothelial cells via phosphatidylinositol 3-kinase- and protein kinase A-dependent signaling pathways to regulate ET-1 synthesis and secretion. J Biol Chem 283:29228-29238
54. Reiter CE, Kim JA, Quon MJ 2010 Green tea polyphenol epigallo-catechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: roles for AMP-activated protein kinase, Akt, and FOXO1. Endocrinology 151:103-114
55. Potenza MA, Marasciulo FL, Tarquinio M, Tiravanti E, Colan-tuono G, Federici A, Kim JA, Quon MJ, Montagnani M 2007 EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 292:E1378-E1387
56. Widlansky ME, Hamburg NM, Anter E, Holbrook M, Kahn DF, Elliott JG, Keaney Jr JF, Vita JA 2007 Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 26:95-102
57. Ou HC, Song TY, Yeh YC, Huang CY, Yang SF, Chiu TH, Tsai KL, Chen KL, Wu YJ, Tsai CS, Chang LY, Kuo WW, Lee SD 2010 EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. J Appl Physiol 108: 1745-1756
58. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A 2003 Insulin-induced phosphorylation of FKHR (Foxo1) targets to pro-teasomal degradation. Proc Natl Acad Sci USA 100:11285-11290
59. Aoki M, Jiang H, Vogt PK 2004 Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci USA 101:13613-13617
60. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ 2005 Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 102:1649-1654
61. Gogg S, Smith U, Jansson PA 2009 Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothe-lial cells in type 2 diabetes: the role of endothelin-1. Diabetes 58: 2238-2245
62. Desideri G, Ferri C, Bellini C, De Mattia G, Santucci A 1997 Effects of ACE inhibition on spontaneous and insulin-stimulated endothe-lin-1 secretion: in vitro and in vivo studies. Diabetes 46:81-86
63. Letizia C, Iannaccone A, Cerci S, Santi G, Cilli M, Coassin S, Pan-narale MR, Scavo D, Iannacone A 1997 Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy. Horm Metab Res 29:247-251
64. Kawamura M, Ohgawara H, Naruse M, Suzuki N, Iwasaki N, Naruse K, Hori S, Demura H, Omori Y 1992 Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 15:1396-1397
65. Wilkes JJ, Hevener A, Olefsky J 2003 Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 52:1904-1909